Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 121,300 shares, a decrease of 22.7% from the December 15th total of 157,000 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 91,200 shares, the short-interest ratio is presently 1.3 days.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. increased its position in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 868,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the period. Chapin Davis Inc. owned 2.97% of Dyadic International worth $903,000 at the end of the most recent reporting period. 27.95% of the stock is currently owned by institutional investors.

Dyadic International Price Performance

NASDAQ DYAI opened at $1.56 on Thursday. The stock has a market capitalization of $46.16 million, a P/E ratio of -6.78 and a beta of 0.89. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. The business’s fifty day moving average is $1.61 and its two-hundred day moving average is $1.39. Dyadic International has a 1 year low of $0.93 and a 1 year high of $2.67.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The company had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. During the same period last year, the company posted ($0.06) earnings per share. On average, research analysts forecast that Dyadic International will post -0.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a report on Thursday, November 14th.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.